ScholarIQanswers from OpenAlex & ORCID
Sattva S. Neelapu
ResearcherPublications, citations & collaboration network
Sattva S. Neelapu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sattva S. Neelapu have?
ScholarIQindexed works
Sattva S. Neelapu has 871 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sattva S. Neelapu have?
ScholarIQcitation count
Sattva S. Neelapu has 44,443 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sattva S. Neelapu?
ScholarIQh-index
Sattva S. Neelapu has an h-index of 85 in OpenAlex.
What is the i10-index of Sattva S. Neelapu?
ScholarIQi10-index
Sattva S. Neelapu has an i10-index of 333 in OpenAlex.
What is the ORCID of Sattva S. Neelapu?
ScholarIQorcid
The ORCID for Sattva S. Neelapu is on the source record.
What is the OpenAlex record for Sattva S. Neelapu?
ScholarIQopenalex
The OpenAlex for Sattva S. Neelapu is on the source record.
What are the most-cited papers on Sattva S. Neelapu?
ScholarIQmost cited works
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Qing Deng, Guangchun Han, Nahum Puebla‐Osorio, Man Chun John, Paolo Strati, Beth Chasen, Enyu Dai, Minghao Dang, Neeraj Jain, Haopeng Yang, Yuanxin Wang, Shaojun Zhang, Ruiping Wang, Runzhe Chen, Jordan Showell, Sreejoyee Ghosh, Sridevi Patchva, Qi Zhang, Ryan Sun, Frederick Hagemeister, Luis Fayad, Felipe Samaniego, Hans C. Lee, Loretta J. Nastoupil, Nathan Fowler, R. Eric Davis, Jason R. Westin, Sattva S. Neelapu, Linghua Wang, Michael R. Green
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Patrizia Mondello, Saber Tadros, Matt Teater, Lorena Fontán, Aaron Y. Chang, Neeraj Jain, Haopeng Yang, Shailbala Singh, Hsia‐Yuan Ying, Chi-Shuen Chu, Man Chun John, Eneda Toska, Stefan Alig, Matthew Durant, Elisa de Stanchina, Sreejoyee Ghosh, Anja Mottok, Loretta J. Nastoupil, Sattva S. Neelapu, Oliver Weigert, Giorgio Inghirami, José Baselga, Anas Younes, Cassian Yee, Ahmet Doǧan, David A. Scheinberg, Robert G. Roeder, Ari Melnick, Michael R. Green